Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SSY GroupHKSE:02005 -0.42%86 OCF Yield % is 9.19 as of Jul. 27, 2026, which is 73% above its 10-year median of 5.32. GuruFocus rates HKSE:02005 with a GF Score™ of 86/100 and a GF Value™ of HK$3.04 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 1,007 Drug Manufacturers companies, SSY Group ranks better than 76.27% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
SSY Group OCF Yield % Related Terms
SSY Group OCF Yield % Historical Data
* Premium members only.
The historical data trend for SSY Group's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, SSY Group's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SSY Group OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SSY Group's OCF Yield % distribution charts can be found below:
* The bar in red indicates where SSY Group's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SSY Group (HKSE:02005) has a OCF Yield % of 9.19 as of Jul. 27, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on SSY Group and its competitors. This is 73% above median its historical median of 5.32. Over the past decade, SSY Group's OCF Yield % has ranged from 2.04 to 10.26. According to the industry distribution chart, SSY Group ranks #239 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 23.7%.
Is SSY Group's OCF Yield % too high?
SSY Group's current OCF Yield % of 9.19 is 73% above median its 10-year median of 5.32. Over the past 10 years, this metric has ranged from a low of 2.04 to a high of 10.26. The Drug Manufacturers industry median OCF Yield % is 3.61. SSY Group's value of 9.19 is 154.6% above this industry median. Based on the distribution chart, SSY Group ranks #239 out of 1007 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, SSY Group has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SSY Group's OCF Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, SSY Group ranks #239 out of 1007 companies for OCF Yield %. This places SSY Group in the top 24% of its industry — outperforming the majority of peers. The industry median OCF Yield % is 3.61. SSY Group's value of 9.19 is 154.6% above this benchmark. Historically, SSY Group's own OCF Yield % has ranged from 2.04 to 10.26 over the past decade. While the company's 10-year median is 5.32 vs. the industry median of 3.61, SSY Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.61, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SSY Group's current OCF Yield % of 9.19 is 154.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on SSY Group and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SSY Group's current OCF Yield % is 9.19, which is 73% above median its own 10-year median of 5.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SSY Group stock overvalued right now?
Based on GuruFocus' analysis, SSY Group (HKSE:02005) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$3.04, compared to a current price of HK$2.39 — trading 21.4% below its estimated fair value. The current OCF Yield % is 9.19, which is 73% above median its 10-year median of 5.32 and 154.6% above the Drug Manufacturers industry median of 3.61. SSY Group's overall GF Score™ is 86/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For SSY Group (HKSE:02005), the current OCF Yield % is 9.19 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SSY Group (HKSE:02005) Overvalued in 2026?
Based on GuruFocus' analysis, SSY Group stock appears to be undervalued.
The current stock price of HK$2.39 is trading 21.4% below its estimated GF Value™ of HK$3.04.
GuruFocus considers SSY Group to be Modestly Undervalued.
Key valuation signals for HKSE:02005:
OCF Yield %: 9.19 (73% above median its 10-year median of 5.32)
GF Value™: HK$3.04 vs. price of HK$2.39 (21.4% below fair value)
Industry Position: 154.6% above the Drug Manufacturers median (#239 of 1007)
No single metric tells the full story. See the HKSE:02005 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SSY Group Ltd is engaged in the research, development, manufacturing, and selling of a wide range of pharmaceutical products, which include finished medicines of mainly intravenous infusion solutions and ampoule injections to hospitals and distributors, bulk pharmaceuticals, and medical materials. The company has two reportable segments, including intravenous infusion solutions and other medical materials. The company derives a vast majority of its revenue principally from the Intravenous infusion solution and others. Revenue generation is driven mostly by its sales of pharmaceutical products. The company derives maximum revenue from PRC.
86GF Score
Get the complete analysis for HKSE:02005
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02005 has been successfully added to your 
